KINETA INC (KA) Stock Price, Forecast & Analysis
USA - NASDAQ:KA - US49461C1027 - Common Stock
KA Key Statistics, Chart & Performance
The current stock price of KA is 0.5746 USD. In the past month the price decreased by -17.62%. In the past year, price decreased by -75.02%.
KA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About KA
Company Profile
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Mercer Island, Washington and currently employs 11 full-time employees. The company went IPO on 2016-02-11. The firm has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. The company is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
Company Info
KINETA INC
7683 Se 27Th Street, Suite 481
Mercer Island WASHINGTON US
Employees: 11
Phone: 12063780400
KINETA INC / KA FAQ
What does KA do?
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Mercer Island, Washington and currently employs 11 full-time employees. The company went IPO on 2016-02-11. The firm has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. The company is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
Can you provide the latest stock price for KINETA INC?
The current stock price of KA is 0.5746 USD. The price decreased by -30.69% in the last trading session.
What is the dividend status of KINETA INC?
KA does not pay a dividend.
How is the ChartMill rating for KINETA INC?
KA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Should I buy KA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KA.
When does KINETA INC (KA) report earnings?
KINETA INC (KA) will report earnings on 2024-11-01, after the market close.
KA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KA. When comparing the yearly performance of all stocks, KA is a bad performer in the overall market: 94.04% of all stocks are doing better.
KA Financial Highlights
Over the last trailing twelve months KA reported a non-GAAP Earnings per Share(EPS) of -1.5. The EPS increased by 68.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1492.21% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KA Forecast & Estimates
9 analysts have analysed KA and the average price target is 13.77 USD. This implies a price increase of 2296.45% is expected in the next year compared to the current price of 0.5746.
For the next year, analysts expect an EPS growth of 3.18% and a revenue growth -100% for KA